| 85.63 1.94 (2.32%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 112.06 | 1-year : | 130.89 |
| Resists | First : | 95.94 | Second : | 112.06 |
| Pivot price | 77.61  |
|||
| Supports | First : | 73.57 | Second : | 59.74 |
| MAs | MA(5) : | 85.97  |
MA(20) : | 74.8 |
| MA(100) : | 61.05 |
MA(250) : | 56.96 |
|
| MACD | MACD : | 6.1 |
Signal : | 5 |
| %K %D | K(14,3) : | 65.1 |
D(3) : | 67.3 |
| RSI | RSI(14): 68.9 |
|||
| 52-week | High : | 95.94 | Low : | 30.81 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ IRON ] has closed below upper band by 24.1%. Bollinger Bands are 287.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 17 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 85.82 - 86.43 | 86.43 - 86.9 |
| Low: | 82.6 - 83.24 | 83.24 - 83.74 |
| Close: | 84.79 - 85.79 | 85.79 - 86.56 |
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.
Fri, 24 Oct 2025
AI DMI LLC sells Disc Medicine (IRON) shares worth $59.8m - Investing.com
Wed, 22 Oct 2025
Does Disc Medicine, Inc. (IRON) Have the Potential to Rally 26.29% as Wall Street Analysts Expect? - Yahoo Finance
Tue, 21 Oct 2025
Disc Medicine, Inc. (IRON) Stock Analysis: Exploring a 22% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews
Tue, 21 Oct 2025
Disc Medicine (IRON) Prices Upsized Offering to Raise $225M - GuruFocus
Tue, 21 Oct 2025
Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants - Yahoo Finance
Mon, 20 Oct 2025
Disc Medicine: NDA Submission, CNPV For Bitopertin Further Boost Shareholder Value (IRON) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 35 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 10.6 (%) |
| Held by Institutions | 99.6 (%) |
| Shares Short | 2,640 (K) |
| Shares Short P.Month | 2,100 (K) |
| EPS | -4.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 17.7 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -18 % |
| Return on Equity (ttm) | -26.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.86 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -134 (M) |
| Levered Free Cash Flow | -89 (M) |
| PE Ratio | -19.2 |
| PEG Ratio | 0 |
| Price to Book value | 4.83 |
| Price to Sales | 0 |
| Price to Cash Flow | -22.19 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|